Bital Savir-Baruch

Chief, Division of Nuclear Medicine and Molecular Imaging | Professor, Medical Imaging - (Clinical Scholar Track)

Research Area

Recent

Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study LIGHTHOUSE)

2023

Computer assisted interpretation of Tc-99m mercaptoacetyltriglycine diuretic scintigraphy enhances resident performance

2023

Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer

2023

Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study SPOTLIGHT)

2023

Impact of F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials

2023

Effect of hormonal therapy on F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen

2022

Positivity Rate of F]Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Below 1 ng/mL

2022

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 Lu-177) DOTATATE Therapy

2022

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

2022

Prostate Cancer Imaging with 18F-Fluciclovine

2022

Page 1 of 4

Bital Savir-Baruch

Research Area

Grants(3)

Publications(41)

Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study LIGHTHOUSE)

Computer assisted interpretation of Tc-99m mercaptoacetyltriglycine diuretic scintigraphy enhances resident performance

Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer

Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study SPOTLIGHT)

Impact of F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials

Effect of hormonal therapy on F-fluciclovine PET/CT in the detection of prostate cancer recurrence, localization of metastatic disease, and correlation with prostate-specific antigen

Positivity Rate of F]Fluciclovine PET/CT in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Below 1 ng/mL

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 Lu-177) DOTATATE Therapy

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

Prostate Cancer Imaging with 18F-Fluciclovine

Collaborations(19)

Rachna Shroff

Gene Alexander

Theodore Trouard

Maria Altbach

Edward Bedrick